(Press-News.org) Clinical stage artificial intelligence (AI) drug discovery company Insilico Medicine (“Insilico”) has been invited to present scientific data on its novel anti-cancer assets at three major upcoming cancer conferences -- the European Society for Medical Oncology (ESMO) conference in Madrid Oct. 20-24, 2023; the Society of Immunotherapy of Cancer (SITC) conference Nov. 1-5, 2023 in San Diego; and the San Antonio Breast Cancer Symposium (SABCS) Dec. 5-9, 2023.
Small molecule oncology target inhibitors represent the largest part of Insilico’s therapeutic pipeline portfolio, which includes 31 programs across 29 targets. The Company recently entered into a licensing deal with Exelixis on its potentially best-in-class generative AI-designed USP1 inhibitor for BRCA-mutant tumors for $80m upfront and additional milestone payments and tiered royalties. That drug is currently in a Phase I clinical trial.
“Using our AI platform, we have been able to advance a number of anti-cancer therapeutics that use new mechanisms to stop tumor growth and cancer progression, including two in clinical stage,” says Sujata Rao, MD, Chief Medical Officer at Insilico Medicine. Dr. Rao has extensive experience in clinical oncology practice and over 15 years in pharma leading global clinical development for cancer drugs. "Driven by a strategy of focusing on novelty, confidence, and commercial tractability, and designed to meet the high unmet medical needs of patients, we have developed a number of promising anti-cancer assets and look forward to presenting to the leading cancer conferences.”
Dr. Rao showcased four of the Company’s novel AI-designed cancer inhibitors at the most recent Association for Cancer Research (AACR) annual meeting.
Insilico’s upcoming cancer conference presentations include:
ESMO - Oct. 20-24: At ESMO, Insilico will present data on ISM8207, a novel QPCTL inhibitor for triple negative breast cancer and B-cell non-Hodgkin lymphoma. The small molecule inhibitor, currently being evaluated in a Phase I trial, has demonstrated anti-tumor activity in both hematological tumors and solid tumors in preclinical studies, as well as favorable pharmacokinetics and safety profiles. This molecule is available for licensing partners in the U.S., Europe and Japan.
SITC - Nov. 1-5: At SITC, Insilico will present data on ISM5939, a novel, potent, orally available, selective ENPP1 inhibitor cancer immunotherapy for multiple tumor types that enhances the anti-tumor effects of immune checkpoint inhibitors in syngeneic murine cancer models. It is also being advanced as a possible treatment for Hypophosphatasia.
SABCS - Dec. 5-9: At SABCS, Insilico will present data on ISM5043, a novel, selective KAT6 inhibitor for the treatment of advanced ER+/HER2- breast cancer - the most common subtype of breast cancer. Current treatment for patients with advanced or metastatic disease is endocrine therapy in combination with CDK4/6 inhibitors but many patients develop resistance to therapy, indicating a huge unmet medical need.
Insilico is advancing new therapeutics using generative AI via its proprietary end-to-end Pharma.AI platform for identifying novel targets (PandaOmics), designing new drugs (Chemistry42), and predicting the outcomes of clinical trials (InClinico). The platform has produced four drugs that have reached clinical trials, including a lead drug for the devastating chronic lung disease Idiopathic Pulmonary Fibrosis (IPF), the first AI-discovered and AI-designed drug to advance to Phase II trials with patients.
“We’re really encouraged by the progress of our diverse pipeline of cancer therapeutics – two of which have progressed into clinical trials,” says Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine. “Our AI can be thought of as a ‘Google for targets’ that looks at every single small signal from massive datasets all over the world, including our own robotics data. It gives us signals that the target is working in a specific cancer, it already has demonstrated some efficacy, and it is going to be commercially tractable.”
Dr. Rao and Insilico’s Chief Business Officer Michelle Chen, PhD, along with other business development professionals, will be in attendance at the upcoming conferences. For any interest in licensing or partnerships, please contact: bd@insilicomedicine.com.
About Insilico Medicine
Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. www.insilico.com
END
Insilico Medicine presents data on AI-designed cancer drugs at 3 major cancer conferences
2023-10-16
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
American Society of Anesthesiologists recognizes Philip G. Morgan, M.D., and Margaret M. Sedensky, M.D., with its Excellence in Research Award
2023-10-16
SAN FRANCISCO — The American Society of Anesthesiologists (ASA) today presented Philip G. Morgan, M.D., and Margaret M. Sedensky, M.D., with its 2023 Excellence in Research Award in recognition of their extensive research focused on understanding how anesthetics work and whether certain anesthetics are safe for children with mitochondrial disease. The award is presented annually for outstanding achievement in research that has had, or is likely to have, an important impact on the practice of anesthesiology.
Drs. Morgan and Sedensky are professors in the Department of Anesthesiology ...
Study reveals areas of Brazilian Amazon where no ecological research has been done
2023-10-16
Many parts of the Brazilian Amazon are neglected in ecological research, for several reasons, according to an article published in the journal Current Biology. Authored by Joice Ferreira of the Federal University of Pará (UFP) and colleagues from many countries who also belong to the Synergize Consortium, the article identifies the areas missing from ecological research and the factors that have determined these gaps, pinpointing opportunities for the planning of new investments in research ...
New polymer membranes, AI predictions could dramatically reduce energy, water use in oil refining
2023-10-16
A new kind of polymer membrane created by researchers at Georgia Tech could reshape how refineries process crude oil, dramatically reducing the energy and water required while extracting even more useful materials.
The so-called DUCKY polymers — more on the unusual name in a minute — are reported Oct. 16 in Nature Materials. And they’re just the beginning for the team of Georgia Tech chemists, chemical engineers, and materials scientists. They also have created artificial intelligence tools to predict the performance of these kinds of polymer membranes, which could accelerate development of new ones.
The implications are stark: ...
Firearm exposure associated with poorer health in communities around the U.S.
2023-10-16
Gun violence is tied to poverty, unemployment, broken families, disengaged youth and racial segregation, according to a study by the New Jersey Gun Violence Research Center at Rutgers.
Published in the Journal of Urban Health, the study found that people living in disadvantaged communities face gun violence at higher levels that are harmful to the health and well-being of whole neighborhoods.
“Many of America’s most disadvantaged neighborhoods are stuck in a vicious cycle of violence and collateral damage that is almost impossible to escape,” ...
Transforming wastewater into valuable chemicals with sunlight
2023-10-16
Researchers led by Prof. GAO Xiang from the Shenzhen Institute of Advanced Technology (SIAT) of the Chinese Academy of Sciences and Prof. LU Lu from the Harbin Institute of Technology have proposed a novel method to transform wastewater contaminants into valuable chemicals using sunlight, thus paving the way for sustainable and eco-friendly chemical manufacturing.
The study was published in Nature Sustainability on Oct. 16.
Conventional chemical manufacturing relies on energy-intensive processes. Semiconductor biohybrids, integrating efficient light-harvesting materials with superior living cells, have emerged as an exciting advancement ...
Viral persistence and serotonin reduction can cause long COVID symptoms, Penn Medicine research finds
2023-10-16
PHILADELPHIA—Patients with long COVID – the long-term symptoms like brain fog, fatigue, or memory loss in the months or years following COVID-19 – can exhibit a reduction in circulating levels of the neurotransmitter serotonin, according to new research published today in Cell. The study, led by researchers from the Perelman School of Medicine at the University of Pennsylvania, sheds new light on the mechanisms of how persistent inflammation after contracting the SARS-CoV-2 virus can cause long-term neurological symptoms.
According to the CDC, nearly one in five American adults who had COVID-19 experience symptoms of long ...
Can ChatGPT diagnose your condition? Not yet
2023-10-16
A research group led by Tokyo Medical and Dental University (TMDU) finds that when common orthopedic symptoms are given, ChatGPT’s diagnosis and recommendations are inconsistent
Tokyo, Japan – ChatGPT, a sophisticated chatbot driven by artificial intelligence (AI) technology, has been increasingly used in health care contexts, one of which is assisting patients in self-diagnosing before seeking medical help. Although it seems very useful at first glance, AI may cause more harm than good to the patient if it is not accurate in its diagnosis and recommendations. A research team from Japan and ...
Leaders in resuscitation science, education and technology commit to 1 million more lives saved each year by 2030
2023-10-16
DALLAS and STAVANGER, Norway, October 16, 2023 — For nearly 20 years, the American Heart Association® (Association) and Laerdal Medical (Laerdal) have together developed and brought resuscitation education, training and technology to the health care market. The Association and Laerdal will now expand their focus beyond education to creating and nurturing health care quality improvement solutions to impact a community “systems of care” approach and influence more positive patient outcomes. This World Restart a Heart Day, the organizations are furthering their collaborative relationship ...
Management zone maps of little use to corn growers, study finds
2023-10-16
CHAMPAIGN, Ill. — A multiyear analysis tested whether management zone maps based on soil conditions, topography or other landscape features can reliably predict which parts of a cornfield will respond best to higher rates of seeding or nitrogen application. The study found that – contrary to common assumptions – crop-plot responses to the same inputs vary significantly from year to year. The most unpredictable factor – the weather – seemed to have the biggest impact on how the crops responded to these inputs.
The ...
Study: Deep neural networks don’t see the world the way we do
2023-10-16
CAMBRIDGE, MA -- Human sensory systems are very good at recognizing objects that we see or words that we hear, even if the object is upside down or the word is spoken by a voice we’ve never heard.
Computational models known as deep neural networks can be trained to do the same thing, correctly identifying an image of a dog regardless of what color its fur is, or a word regardless of the pitch of the speaker’s voice. However, a new study from MIT neuroscientists has found that these models often also respond the same way to images or words that have no resemblance to the target.
When these neural networks were used to generate an image ...